Alfredo Perales‐Puchalt

4.1k total citations · 2 hit papers
71 papers, 2.9k citations indexed

About

Alfredo Perales‐Puchalt is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Alfredo Perales‐Puchalt has authored 71 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Immunology, 31 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Alfredo Perales‐Puchalt's work include Immunotherapy and Immune Responses (24 papers), Cancer Immunotherapy and Biomarkers (15 papers) and CAR-T cell therapy research (14 papers). Alfredo Perales‐Puchalt is often cited by papers focused on Immunotherapy and Immune Responses (24 papers), Cancer Immunotherapy and Biomarkers (15 papers) and CAR-T cell therapy research (14 papers). Alfredo Perales‐Puchalt collaborates with scholars based in United States, Spain and New Zealand. Alfredo Perales‐Puchalt's co-authors include José R. Conejo-García, Melanie R. Rutkowski, David B. Weiner, Nikolaos Svoronos, Michael J. Allegrezza, Jenny Nguyen, Julia Tchou, Amelia J. Tesone, Tom L. Stephen and Divya Gupta and has published in prestigious journals such as Cell, Nature Medicine and Nature Communications.

In The Last Decade

Alfredo Perales‐Puchalt

68 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis

2015 684 citations Juan R. Cubillos‐Ruiz, Pedro C. Silberman et al. Cell profile →
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

2024 111 citations Mark Yarchoan, Edward Gane et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfredo Perales‐Puchalt United States	26	1.4k	1.1k	999	331	287	71	2.9k
Giuseppe Sconocchia Italy	32	1.2k 0.9×	1.1k 1.0×	698 0.7×	196 0.6×	125 0.4×	88	2.6k
Frederick D. Goldman United States	29	890 0.6×	427 0.4×	1.3k 1.3×	244 0.7×	156 0.5×	69	3.0k
David P. Curley United States	18	560 0.4×	954 0.9×	2.2k 2.2×	158 0.5×	140 0.5×	24	3.5k
Yutaka Suehiro Japan	36	628 0.5×	1.4k 1.3×	1.6k 1.6×	411 1.2×	495 1.7×	144	3.5k
Noelyn M. Kljavin United States	24	1.8k 1.3×	1.3k 1.2×	1.5k 1.5×	333 1.0×	221 0.8×	29	4.1k
Fraia Melchionda Italy	27	552 0.4×	435 0.4×	769 0.8×	325 1.0×	232 0.8×	59	2.0k
Nobuhiro Tsukada Japan	20	1.2k 0.9×	658 0.6×	750 0.8×	227 0.7×	110 0.4×	140	2.9k
Melanie R. Rutkowski United States	26	1.6k 1.1×	1.3k 1.1×	1.2k 1.2×	411 1.2×	273 1.0×	45	3.2k
Norio Asou Japan	34	1.0k 0.7×	783 0.7×	2.4k 2.4×	184 0.6×	149 0.5×	180	4.8k
Jianxun Song United States	32	2.1k 1.5×	1.1k 1.0×	1.2k 1.2×	427 1.3×	206 0.7×	94	3.8k

Countries citing papers authored by Alfredo Perales‐Puchalt

Since Specialization

Citations

This map shows the geographic impact of Alfredo Perales‐Puchalt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfredo Perales‐Puchalt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfredo Perales‐Puchalt more than expected).

Fields of papers citing papers by Alfredo Perales‐Puchalt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfredo Perales‐Puchalt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfredo Perales‐Puchalt. The network helps show where Alfredo Perales‐Puchalt may publish in the future.

Co-authorship network of co-authors of Alfredo Perales‐Puchalt

This figure shows the co-authorship network connecting the top 25 collaborators of Alfredo Perales‐Puchalt. A scholar is included among the top collaborators of Alfredo Perales‐Puchalt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfredo Perales‐Puchalt. Alfredo Perales‐Puchalt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yarchoan, Mark, Edward Gane, Thomas U. Marron, et al.. (2024). Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature Medicine. 30(4). 1044–1053. 111 indexed citations breakdown →

Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S477–S477. 2 indexed citations

Park, Daniel H., Kevin Liaw, Pratik Bhojnagarwala, et al.. (2023). Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape. Molecular Therapy — Oncolytics. 28. 249–263. 11 indexed citations

Bordoloi, Devivasha, Pratik Bhojnagarwala, Alfredo Perales‐Puchalt, et al.. (2022). A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy. JCI Insight. 7(22). 14 indexed citations

Zhu, Xizhou, Alfredo Perales‐Puchalt, Ziyang Xu, et al.. (2021). DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas. Molecular Therapy — Oncolytics. 24. 218–229. 5 indexed citations

Yarchoan, Mark, Edward Gane, Thomas U. Marron, et al.. (2021). 453 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma. SHILAP Revista de lepidopterología. A481–A481. 8 indexed citations

Duperret, Elizabeth K., Alfredo Perales‐Puchalt, Regina Stoltz, et al.. (2019). A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge. Cancer Immunology Research. 7(2). 174–182. 91 indexed citations

Lueck, John D., Jae Seok Yoon, Alfredo Perales‐Puchalt, et al.. (2019). Engineered transfer RNAs for suppression of premature termination codons. Nature Communications. 10(1). 822–822. 105 indexed citations

Perales‐Puchalt, Alfredo, Elizabeth K. Duperret, Xue Yang, et al.. (2019). DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. JCI Insight. 4(8). 36 indexed citations

10.

Duperret, Elizabeth K., Regina Stoltz, Ami Patel, et al.. (2018). Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Research. 78(22). 6363–6370. 49 indexed citations

11.

Duperret, Elizabeth K., Shujing Liu, Regina Stoltz, et al.. (2018). A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clinical Cancer Research. 24(23). 6015–6027. 36 indexed citations

12.

Duperret, Elizabeth K., Dylan T. Ammons, Alfredo Perales‐Puchalt, et al.. (2017). Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clinical Cancer Research. 24(5). 1190–1201. 125 indexed citations

13.

Muthumani, Kar, Sagar B. Kudchodkar, Alfredo Perales‐Puchalt, et al.. (2017). Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunology Immunotherapy. 66(12). 1577–1588. 31 indexed citations

14.

Svoronos, Nikolaos, Alfredo Perales‐Puchalt, Michael J. Allegrezza, et al.. (2016). Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discovery. 7(1). 72–85. 152 indexed citations

15.

Perales‐Puchalt, Alfredo, Nikolaos Svoronos, Melanie R. Rutkowski, et al.. (2016). Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clinical Cancer Research. 23(2). 441–453. 82 indexed citations

16.

Cubillos‐Ruiz, Juan R., Pedro C. Silberman, Melanie R. Rutkowski, et al.. (2015). ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell. 161(7). 1527–1538. 684 indexed citations breakdown →

17.

García‐Tejedor, Amparo, et al.. (2015). Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. European Journal of Obstetrics & Gynecology and Reproductive Biology. 194. 173–177. 39 indexed citations

18.

Perales‐Puchalt, Alfredo & Richard S. Legro. (2013). Ovulation induction in women with polycystic ovary syndrome. Steroids. 78(8). 767–772. 36 indexed citations

19.

Kondapalli, Laxmi A. & Alfredo Perales‐Puchalt. (2013). Low birth weight: is it related to assisted reproductive technology or underlying infertility?. Fertility and Sterility. 99(2). 303–310. 64 indexed citations

20.

Perales‐Puchalt, Alfredo, et al.. (2012). Effect of delayed umbilical cord clamping on blood gas analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 162(1). 21–23. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact